<DOC>
	<DOCNO>NCT01909908</DOCNO>
	<brief_summary>The Extracellular Matrix ( ECM ) Blood Components Wound Healing feasibility study clinical trial approve Health Canada study safety extracellular matrix ( ECM ) autologous blood product wound healing .</brief_summary>
	<brief_title>ECM Blood Components Wound Healing</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Type 1 Type 2 diabetes , and/or venous insufficiency affect leg Ulcer present 12 52 week Ulcer le 40 cm2 area Less 18 year age Pregnant planning become pregnant study period Simultaneously participate another investigational drug device study Unable unwilling comply weekly study followup schedule offload regimen Patient legal representative refuse sign ECapproved inform consent form Known allergy pig porcine product Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Wounds injury</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Diabetic angiopathy</keyword>
	<keyword>Diabetic foot</keyword>
	<keyword>Venous insufficiency</keyword>
	<keyword>Extracellular matrix</keyword>
</DOC>